Search results
Found 58 matches for
Joining the study
ASCEND PLUS is a clinical trial being conducted across the UK. About 20,000 people aged 55 or above are being invited to take part in the study. By joining this study you would help us to find out how to protect people with type 2 diabetes from serious heart and circulatory problems and other health problems. The study aims to find out if regularly taking oral semaglutide, a once-daily tablet medication for type 2 diabetes, can help to prevent heart attacks, strokes or mini-strokes, the need for heart artery ‘balloon’ and bypass procedures, and death from heart and circulatory conditions.
Health professionals
ASCEND PLUS is a national randomised controlled trial designed to investigate the effects of oral semaglutide on major adverse cardiovascular events and other complications among patients with type 2 diabetes but no history of myocardial infarction or stroke. The study aims to recruit 20,000 such patients in the UK. ASCEND PLUS is coordinated by the Clinical Trial Service Unit part of Oxford Population Health and is sponsored by the University of Oxford. Patients with type 1 diabetes, and women who are breastfeeding, pregnant or planning a pregnancy are not eligible to join the trial.